Alliancebernstein L.P. Cerevel Therapeutics Holdings, Inc. Transaction History
Alliancebernstein L.P.
- $275 Billion
- Q1 2024
A detailed history of Alliancebernstein L.P. transactions in Cerevel Therapeutics Holdings, Inc. stock. As of the latest transaction made, Alliancebernstein L.P. holds 1,172,887 shares of CERE stock, worth $48.4 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
1,172,887
Previous 1,132,640
3.55%
Holding current value
$48.4 Million
Previous $48 Million
3.24%
% of portfolio
0.02%
Previous 0.02%
Shares
9 transactions
Others Institutions Holding CERE
# of Institutions
227Shares Held
150MCall Options Held
939KPut Options Held
961K-
Bain Capital Investors LLC Boston, MA65.7MShares$2.71 Billion61.94% of portfolio
-
Perceptive Advisors LLC New York, NY10.8MShares$445 Million9.58% of portfolio
-
Avoro Capital Advisors LLC New York, NY7.56MShares$312 Million3.85% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.46MShares$308 Million0.01% of portfolio
-
Black Rock Inc. New York, NY5.45MShares$225 Million0.01% of portfolio
About Cerevel Therapeutics Holdings, Inc.
- Ticker CERE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 155,752,000
- Market Cap $6.42B
- Description
- Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...